Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2017 06/20/2017 06/21/2017 06/22/2017 06/23/2017 Date
64.82(c) 65.59(c) 67.5(c) 70.48(c) 70.33 Last
7 900 091 13 114 602 13 981 339 28 962 895 8 824 401 Volume
+1.09% +1.19% +2.91% +4.41% -0.21% Change
More quotes
Financials ($)
Sales 2017 24 666 M
EBIT 2017 14 966 M
Net income 2017 9 810 M
Debt 2017 5 653 M
Yield 2017 2,99%
Sales 2018 22 409 M
EBIT 2018 13 236 M
Net income 2018 8 757 M
Debt 2018 6 097 M
Yield 2018 3,20%
P/E ratio 2017 9,43
P/E ratio 2018 10,43
EV / Sales2017 3,96x
EV / Sales2018 4,38x
Capitalization 92 098 M
More Financials
Company
Gilead Sciences, Inc. is a biopharmaceutical company, which discovers, develops and commercializes therapeutics for unmet medical need.It focuses on human immunodeficiency virus and liver diseases, such as chronic hepatitis C virus infection & chronic hepatitis B virus infection, hematology &... 
More about the company
Surperformance© ratings of Gilead Sciences
Trading Rating : Investor Rating :
More Ratings
Latest news on GILEAD SCIENCES
01:36p GILEAD SCIENCES : European CHMP Adopts Positive Opinion for Gilead’s Vosev..
01:15pDJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/22 GILEAD SCIENCES : Submits New Drug Application to U.S. Food and Drug Administrat..
06/22 GILEAD SCIENCES : Patent Issued for Methods for Preparing Anti-Viral Nucleotide ..
06/21 GILEAD SCIENCES : Biotech Industry Showing Signs of a Revival in 2017: Today's R..
06/19 GILEAD SCIENCES : Receives Approval in Canada for VEMLIDY™ (Tenofovir Alaf..
06/16 GILEAD SCIENCES : submits drug application to FDA for HIV treatment
06/15 GILEAD SCIENCES : New Antibiotics Study Findings Have Been Reported by Researche..
06/15 GILEAD SCIENCES : CONTRACT AWARD - 65-- Bristo-Myers Squibb & Gilead Sciences, L..
06/15 GILEAD SCIENCES : submits drug application to FDA for HIV treatment
More news
Sector news : Bio Therapeutic Drugs
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
06/14 JOHNSON & JOHNSON : flu drug succeeds in mid-stage trial
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on GILEAD SCIENCES 
2014A valuable trading opportunity
2014Continuation of the bullish trend
More Strategies
Latest Tweets
01:40p$GILD CHMP Positive Opinion for Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) ..
2
12:29p$GILD initiated at Buy at Deutsche Bank. PT $79
5
04:51aGilead Sciences's market perform rating reiterated at Leerink Swann.  
12:42aGilead calls yield gigantic returns
1
12:42aGilead calls yield gigantic returns
2
More tweets
Qtime:304
News from SeekingAlpha
06/22 Drug stocks rally on GOP draft of healthcare bill
06/22 GILEAD : The Conundrum
06/21 Biotechs blaze as Trump draft order on drug prices would ease regulations
06/21 Biotechs ripping, IBB up almost 8% in three days
06/20 DIVGRO PULSE : June 2017
Advertisement
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 77,7 $
Spread / Average Target 10%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES-1.58%92 098
AMGEN18.88%127 827
CELGENE CORPORATION15.49%104 381
REGENERON PHARMACEUTIC..42.20%55 965
VERTEX PHARMACEUTICALS83.02%33 756
ACTELION23.47%30 485
More Results